Salonpas Spreads Into OTC Diclofenac Arthritis Gel
Hisamitsu America launches Salonpas Arthritis Pain Relief Gel with same active ingredient, diclofenac sodium 1% gel, that became available OTC for the first time in the US in 2020 with GSK’s Voltaren Arthritis Pain formulation.
You may also be interested in...
Hisamitsu America launches online portal exclusively for health care professionals. Also in OTC topical space, Beutlich Pharmaceuticals extends HurriCaine benzocaine gel and spray line with oral anesthetic single-dose packages in five flavors.
Hisamitsu America’s severity of pain claims for Salonpas challenged by GSK are more nuanced than what label indications support, but touting its regulatory approval doesn’t convey a message that other products aren’t subject to as rigorous pre-market evaluations.
CDER’s August-September OTC application approvals are highlighted by Arbor Pharmaceuticals’ ivermectin 0.5% lice treatment. Orange Book changes also include four firms’ approvals for labeling to market generic equivalents of Voltaren Arthritis Relief launched as an OTC switch since earlier in 2020.